A Phase 2, international, multicenter, randomized, open-label, parallel group study to evaluate the efficacy and safety of CC-486 (Oral Azacitidine) Alone and in combination with the Durvalumab (MEDI14736) in subjects with Myelodysplastic Syndromes who fail to achieve an Objective response to treatment with Azacitidine for Injection of Decitabine

Project: Research

Project Details

Project Description

NMA Reference Number: HREC/16/RAH/69
SSA Reference Number: SSA/16/MonH/264
Monash Health HREC Ref: 16385X
StatusFinished
Effective start/end date12/06/19 → 11/06/24

Keywords

  • clinical trial
  • treatment efficacy
  • myeloma

Clinical Trial Phase

  • Phase II